SSG
CBAY

Summit Securities Group’s Cymabay Therapeutics CBAY Stock Holding History

Summit Securities Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,405
Closed -$199K – 990
2023
Q4 		$199K Buy
+8,405
New +$150K 0.02% 252

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Summit Securities Group's CBAY Position: Q1 2024 in Review

Summit Securities Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 8,405 shares — an estimated $199K sold.

Summit Securities Group first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $199K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Summit Securities Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Summit Securities Group sold 8,405 Cymabay Therapeutics shares in Q1 2024, an estimated $199K.
  • Summit Securities Group first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
  • Summit Securities Group's Cymabay Therapeutics position peaked at $199K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Summit Securities Group's 13F filing for Q1 2024, filed 13 May 2024.